Medical Condition News

RSS

Phase 2a clinical trial results of VX-809 in patients with CF announced

Vertex Pharmaceuticals Incorporated today announced results from a preliminary analysis of data from a 28-day Phase 2a clinical trial of VX-809 in patients with cystic fibrosis (CF) who are homozygous for the F508del mutation.

4 Feb 2010

Researchers discover anomalies that cause lack of motivation in ADHD children

Until now, attention-deficit/hyperactivity disorder (ADHD) was related to alterations in the brain affecting attention and cognitive processes. Researchers at Universitat Aut-noma de Barcelona and the Vall d'Hebron University Hospital for the first time have discovered anomalies in the brain's reward system related to the neural circuits of motivation and gratification.

3 Feb 2010

Major study of perfusion imaging under way to assess value of alternative diagnostic methods

Cardiologists and heart imaging specialists at 15 medical centers in eight countries, and led by researchers at Johns Hopkins, have enrolled the first dozen patients in a year-long investigation to learn whether the subtle squeezing of blood flow through the inner layers of the heart is better than traditional SPECT nuclear imaging tests and other diagnostic radiology procedures for accurately tracking the earliest signs of coronary artery clogs.

3 Feb 2010

Keryx Biopharmaceuticals reaches agreement with FDA on SPA for Phase 3 trial of KRX-0401

Keryx Biopharmaceuticals, Inc. announced today that it has reached agreement with the U.S. Food and Drug Administration (FDA) regarding a Special Protocol Assessment (SPA) on the design of a Phase 3 trial for its PI3K/Akt pathway inhibitor, KRX-0401 (perifosine), in patients with refractory metastatic colorectal cancer.

3 Feb 2010

Study shows Cymbalta reduces chronic low back pain

In a new study, 60 mg of Cymbalta® (duloxetine HCl) taken once daily significantly reduced chronic low back pain, as measured by the Brief Pain Inventory (BPI) average pain rating, compared with placebo.

3 Feb 2010

FDA approves Labopharm's OLEPTRO antidepressant for MDD

Labopharm Inc. today announced the U.S. Food and Drug Administration (FDA) has approved OLEPTRO(TM) (trazodone hydrochloride) Extended Release Tablets, a novel once-daily formulation of the antidepressant trazodone, for the treatment of major depressive disorder (MDD) in adults. OLEPTRO(TM) utilizes CONTRAMID(R), Labopharm's clinically validated technology that controls the release of active substances within oral medications.

3 Feb 2010

Daiichi Sankyo initiates Phase III trial of edoxaban in reducing recurrent VTE complications

Daiichi Sankyo Company, Limited, announced today that it has initiated a new large-scale pivotal Phase III trial for edoxaban, its investigational oral Factor Xa inhibitor. This new study, called HOKUSAI (pronounced hoe·koo·sigh) VTE, is evaluating the safety and efficacy of edoxaban in reducing recurrent venous thromboembolic (VTE) complications in patients with deep vein thrombosis (DVT) and/or pulmonary embolism (PE).

3 Feb 2010

BRAF drugs may accelerate tumour growth in cancer patients with faulty RAS gene

A team of UK scientists has made the unexpected discovery that drugs which target a well known fault in a protein called BRAF could actually fuel the progression of cancer in some cases. The findings of this study, which was jointly funded by Cancer Research UK, The Institute of Cancer Research (ICR) and the Wellcome Trust are published in Cell.

3 Feb 2010

Ambassadors of Purple selected to help promote Purple Day for Epilepsy

As the third annual, worldwide Purple Day for Epilepsy approaches on March 26, 2010, organizers in Canada and in 15 other participating countries around the globe are looking for volunteers to promote epilepsy awareness in local communities.

3 Feb 2010

AMPYRA for MS: Acorda Therapeutics announces wholesale pricing and patient assistance program

Acorda Therapeutics, Inc. today announced the wholesale acquisition cost (WAC) for AMPYRA™ (dalfampridine) Extended Release Tablets will be $1,056 per 30-day supply (60-count pill bottle), an annual cost of $12,850. AMPYRA was approved on January 22, 2010 by the U.S. Food and Drug Administration (FDA) as a treatment to improve walking in patients with multiple sclerosis (MS). This was demonstrated by an increase in walking speed. AMPYRA is expected to be available in March 2010.

3 Feb 2010

Innovative discharge program reduces congestive heart failure readmissions

An innovative discharge program developed by Saddleback Memorial Medical Center combining coordination of hospital and community resources, strong patient education and the IDEAL LIFE Bluetooth-enabled wireless remote health monitoring system has helped to reduce congestive heart failure (CHF) readmissions by 50 percent

3 Feb 2010

Penn Medicine experts available to offer medical insight and commentary during 2010 Winter Olympics

Experts from the University of Pennsylvania School of Medicine are available to offer expert medical insight and commentary during the 2010 Winter Olympics in Vancouver on issues ranging from the effects of performance enhancing drugs to concerns about the spread of novel H1N1, head trauma and more.

3 Feb 2010

Go Red For Women launches nationwide call inviting women to Speak Up about heart disease

Too many women die each year because they are unaware that heart disease is their No. 1 killer. Right now, one in three women die of cardiovascular disease and 90 percent of women have one or more risk factors for developing heart disease in the future.

3 Feb 2010

Iodoprovidone exhibits safety and efficiency in management of malignant pleural effusion

In the USA each year, 200,000 cancer patients suffer from a malignant pleural effusion - development of excessive fluid (pleural effusion) in the chest. Several litres of such fluid can accumulate, and many patients suffer from significant breathlessness and distress. One in four patients with lung cancer, one in every three with breast cancer and most of the patients with mesothelioma will develop a malignant effusion.

3 Feb 2010

LLS increases maximum benefit for myeloma patients to $10,000

The Leukemia & Lymphoma Society (LLS) is pleased to announce that, effective Feb. 1, 2010, patients with myeloma and waldenstrom macroglobulinemia will now be able to receive up to $10,000 in support to help offset the costs of prescription drug co-pays and other insurance related expenses.

3 Feb 2010

Certain cancer surgeries for low-risk patients may be performed at community hospitals

Low-risk patients who require certain cancer surgeries can have the procedures performed with low operative mortality rates at community hospitals, according to a new study.

3 Feb 2010

Apple Valley Medical Center to hold free Heart Failure Community Education Evening

A free Heart Failure Community Education Evening will be held from 6:00 p.m. to 8:00 p.m. on Tuesday, February 9, 2010, at the Apple Valley Medical Center.

3 Feb 2010

Research retraction underscores the safety and efficacy of MMR vaccines

The Lancet, a premier British medical journal, today retracted a study published in 1998 that drew a link between the measles, mumps and rubella (MMR) vaccine and increased incidence of autism.

3 Feb 2010

Is there a link to rising rates of autism, ADHD and other learning and developmental disabilities?

Jeff Sell, father of twin sons with autism ,Vice President for Policy at the Autism Society; Maureen H. Swanson, Healthy Children Project Coordinator, Learning Disabilities Association of America; Larry Silver MD, author of the Understanding and Coping with Your Child's Learning Disabilities; and others will join Andy Igrejas, National Campaign Director of the Safer Chemicals, Healthy Families Campaign on a national telephone news briefing for the release of Mind, Disrupted: How Toxic Chemicals May Affect How We Think and Who We Are, produced by the Learning and Developmental Disabilities Initiative (LDDI).

3 Feb 2010

Research opens new avenues for understanding genetic basis of type 2 diabetes

Together with colleagues in Barcelona, researchers at the University of North Carolina at Chapel Hill have generated a complete map of the areas of the genome that control which genes are "turned on" or "off."

3 Feb 2010

Medical Condition News

Phase 2a clinical trial results of VX-809 in patients with CF announced

Researchers discover anomalies that cause lack of motivation in ADHD children

Major study of perfusion imaging under way to assess value of alternative diagnostic methods

Keryx Biopharmaceuticals reaches agreement with FDA on SPA for Phase 3 trial of KRX-0401

Study shows Cymbalta reduces chronic low back pain

FDA approves Labopharm's OLEPTRO antidepressant for MDD

Daiichi Sankyo initiates Phase III trial of edoxaban in reducing recurrent VTE complications

BRAF drugs may accelerate tumour growth in cancer patients with faulty RAS gene

Ambassadors of Purple selected to help promote Purple Day for Epilepsy

AMPYRA for MS: Acorda Therapeutics announces wholesale pricing and patient assistance program

Innovative discharge program reduces congestive heart failure readmissions

Penn Medicine experts available to offer medical insight and commentary during 2010 Winter Olympics

Go Red For Women launches nationwide call inviting women to Speak Up about heart disease

Iodoprovidone exhibits safety and efficiency in management of malignant pleural effusion

LLS increases maximum benefit for myeloma patients to $10,000

Certain cancer surgeries for low-risk patients may be performed at community hospitals

Apple Valley Medical Center to hold free Heart Failure Community Education Evening

Research retraction underscores the safety and efficacy of MMR vaccines

Is there a link to rising rates of autism, ADHD and other learning and developmental disabilities?

Research opens new avenues for understanding genetic basis of type 2 diabetes

Real-time Raman monitoring for pharmaceutical hot melt extrusion

Synthetic Psychedelics: A Growing Public Health Concern

How the Vutara VXL simplifies single-molecule imaging

Latest News